Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer
2021 · JAMA Oncology · 104 citations
https://doi.org/10.1001/jamaoncol.2021.3690
S
Shi Wei
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
489
Papers
9.6K
Citations
50
h-index
164
i10-index
Shi Wei is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Breast Cancer Treatment Studies & Sarcoma Diagnosis and Treatment & Epigenetics and DNA Methylation. The author has an h-index of 50, co-authored 416 publications.
ORCID: 0000-0003-4417-593XPapers by this author
worksMetabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion
2022 · Nature Communications · 95 citations
https://doi.org/10.1038/s41467-022-34064-4
Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution
2020 · Modern Pathology · 60 citations
https://doi.org/10.1038/s41379-020-0615-z
Differential timing of granule cell production during cerebellum development underlies generation of the foliation pattern
2016 · Neural Development · 49 citations
https://doi.org/10.1186/s13064-016-0072-z
Breast carcinomas with isolated bone metastases have different hormone receptor expression profiles than those with metastases to other sites or multiple organs
2010 · Annals of Diagnostic Pathology · 43 citations
https://doi.org/10.1016/j.anndiagpath.2010.06.010
Characterization of estrogen receptor-low-positive breast cancer
2021 · Breast Cancer Research and Treatment · 43 citations
https://doi.org/10.1007/s10549-021-06148-0
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat